Cancer and the cyclo-oxygenase enzyme: Implications for treatment and prevention

American Journal of Cancer

Volumn 2, Issue 1, 2003, Pages 27-55

  Hawk, Ernest T ^a   Viner, Jaye L ^a   Umar, Asad ^a   Anderson, William F ^a   Sigman, Caroline C ^b   Guyton, Kate Z ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CCS Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROSTANOID; ROFECOXIB; THROMBOXANE;

ANGIOGENESIS; APOPTOSIS; BREAST CARCINOMA; CANCER CELL; CANCER GROWTH; CANCER PREVENTION; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COLON CARCINOMA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; LUNG CARCINOMA; METASTASIS; PRECANCER; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROSTATE CARCINOMA; REVIEW;

EID: 0041821607     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200302010-00003     Document Type: Review

References (382)

1. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000 Jan 1; 69 (1): 145-82
2. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38: 97-120
3. Needleman P, Turk J, Jakschik BA, et al. Arachidonic acid metabolism. Annu Rev Biochem 1986; 55: 69-102
4. Lupulescu A. Prostaglandins: their inhibitors and cancer. Prostaglandins Leukot Essent Fatty Acids 1996 Feb; 54 (2): 83-94
5. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996; 271 (52): 331-57-60
6. Williams CS, DuBois RN. Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol 1996; 270 (3 Pt 1): G393-400
7. Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta 1996; 1299 (1): 125-40
8. Howe LR, Subbaramaiah K, Brown AM, et al. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 2001 Jun; 8 (2): 97-114
9. Howe LR, Crawford HC, Subbaramaiah K, et al. PEA3 is up-regulated in response to Wnt1 and activates the expression of cyclooxygenas-2. J Biol Chem 2001 June 8; 276 (23): 20108-20115
10. Xie W, Herschman HR. V-src induces prostaglandin synthase 2 gene expression by activation of the c-Jun N-terminal kinase and the c-Jun transcription factor. J Biol Chem 1995; 270 (46): 27622-8
11. Subbaramiah K, Norton L, Gerald W, et al. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 2002; 277 (21): 18649-57
12. Sheng H, Shao J, Morrow JD, et al. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998; 58 (2): 362-6
13. Vadlamudi R, Mandal M, Adam L, et al. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 1999; 18 (2): 305-14
14. Chen G, Wilson R, McKillop JH, et al. The role of cytokines in the production of prostacyclin and thromboxane in human mononuclear cells. Immunol Invest 1994; 23 (4-5): 269-79
15. Subbaramaiah K, Telang N, Ramonetti JT, et al. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 1996; 56 (19): 4424-9
16. Subbarayan V, Sabichi AL, Llansa N, et al. Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells. Cancer Res 2001; 61 (6): 2720-6
17. Herschman HR. Function and regulation of prostaglandin synthase 2. Adv Exp Med Biol 1999; 469: 3-8
18. Ramsay RG, Friend A, Vizantios Y, et al. Cyclooxygenase-2, a colorectal cancer nonsteroidal anti-inflammatory drug target, is regulated by c-MYB. Cancer Res 2000 Apr 1; 60-(7): 1805-9
19. Gorgoni B, Caivano M, Arizmendi C, et al. The transcription factor C/EBPbeta is essential for inducible expression of the cox-2 gene in macrophages but not in fibroblasts. J Biol Chem 2001 Nov 2; 276 (44): 40769-77
20. Xie W, Herschman HR. Transcriptional regulation of prostaglandin synthase 2 gene expression by platelet-derived growth factor and serum. J Biol Chem 1996; 271 (49): 31742-8
21. Subbaramaiah K, Chung WJ, Dannenberg AJ. Ceramide regulates the transcription of cyclooxygenase-2: evidence for involvement of extracellular signal-regulated kinase/c-Jun N-terminal kinase and p38 mitogen-activated protein kinase pathways. J Biol Chem 1998 Dec 4; 273 (49): 32943-9
22. Chen C-C, Sun Y-T, Chen J-J, et al. Tumor necrosis factor-alpha-induced cyclooxygenase-2 expression via sequential activation of ceramide-dependent mitogen-activated protein kinases, and I-kappaB kinase 1/2 in human alveolar epithelial cells. Mol Pharmacol 2001 Mar 1; 59 (3): 493-500
23. Srivastava SK, Tetsuka T, Daphna-Iken D, et al. IL-1 beta stabilizes COX II mRNA in renal mesangial cells: role of 3′-untranslated region. Am J Physiol 1994 Sep; 267 (3 Pt 2): F504-8
24. Cok SJ, Morrison AR. The 3′-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and transla-tional efficiency. J Biol Chem 2001 Jun 22; 276 (25): 23179-85
25. Dixon DA, Tolley ND, King PH, et al. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J Clin Invest 2001 Dec; 108 (11): 1657-65
26. Sheng H, Shao J, Dixon DA, et al. Transforming growth factor-betal enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J Biol Chem 2000 Mar 3; 275 (9): 6628-35
27. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107 (4): 1183-8
28. Kargman SL, O'Neill GP, Vickers PJ, et al. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995; 55 (12): 2556-9
29. Kutchera W, Jones DA, Matsunami N, et al. Prostaglandin H synthase 2 is ex-pressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci U S A 1996; 93 (10): 4816-20
30. Gustafson-Svard C, Lilja I, Hallbook O, et al. Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats. Gut 1996; 38 (1): 79-84
31. Fujita T, Matsui M, Takaku K, et al. Takaku Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 1998; 58 (21): 4823-6
32. Maekawa M, Sugano K, Sano H, et al. Increased expression of cyclooxygenase-2 to -1 in human colorectal cancers and adenomas, but not in hyperplastic polyps. Jpn J Clin Oncol 1998; 28 (7): 421-6.
33. Sinicrope FA, Lemoine M, Xi L, et al. Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. Gastroenterology 1999; 117 (2): 350-8
34. Sheehan KM, Sheahan K, O'Donoghue DP, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999; 282 (13): 1254-7
35. Shattuck-Brandt RL, Lamps LW, Heppner Goss KJ, et al. Differential expression of matrilysin and cyclooxygenase-2 in intestinal and colorectal neoplasms. Mol Carcinog 1999; 24 (3): 177-87
36. Sakuma K, Fujimori T, Hirabayashi K, et al. Cyclooxygenase (COX)-2 immuno-reactivity and relationship to p53 and Ki-67 expression in colorectal cancer. J Gastroenterol 1999; 34 (2): 189-94
37. Hao X, Bishop AE, Wallace M, et al. Early expression of cyclooxygenase-2 during sporadic colorectal carcinogenesis. J Pathol 1999; 187 (3): 295-301
38. Bamba H, Ota S, Kato A, et al. High expression of cyclooxygenase-2 in macrophages of human colonic adenoma. Int J Cancer 1999; 83 (4): 470-5
39. Dimberg J, Samuelsson A, Hugander A, et al. Differential expression of cyclooxygenase 2 in human colorectal cancer. Gut 1999; 45 (5): 730-2
40. Tomozawa S, Tsuno NH, Sunami E, et al. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 2000; 83 (3): 324-8
41. Masunaga R, Kohno H, Dhar DK, et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000; 6 (10): 4064-8
42. Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000; 89 (12): 2637-45
43. Hull MA, Fenwick SW, Chapple KS, et al. Cyclooxygenase-2 expression in colorectal cancer liver metastases. Clin Exp Mctastasis 2000; 18 (1): 21-7
44. Fujita M, Fukui H, Kusaka T, et al. Relationship between cyclooxygenase-2 ex-pression and K-ras gene mutation in colorectal adenomas. J Gastroenterol Hepatol 2000; 15 (11): 1277-81
45. Chapple KS, Cartwright EJ, Hawcroft G, et al. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. Am J Pathol 2000; 156 (2): 545-53
46. Arbabi S, Rosengart MR, Garcia I, et al. Epithelial cyclooxygenase-2 expression: a model for pathogenesis of colon cancer. J Surg Res 2001; 97 (1): 60-4
47. Chen WS, Wei SJ, Liu JM, et al. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer 2001; 91 (6): 894-9
48. Yoshimura R, Sano H, Mitsuhashi M, et al. Expression of cyclooxygenase-2 in patients with bladdcr carcinoma. J Urol 2001 May; 165 (5): 1468-72
49. Bostrom PJ, Uotila P, Rajala P, et al. Interferon-alpha inhibits cyclooxygenase-1 and stimulates cyclooxygenase-2 expression in bladder cancer cells in vitro. Urol Res 2001; 29 (1): 20-4
50. Komhoff M, Guan Y, Shappell HW, et al. Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol 2000; 157 (1): 29-35.
51. Mohammed SI, Knapp DW, Bostwick DG, et al. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 1999; 59 (22): 5647-50
52. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002 Feb 1; 62 (3): 632-5
53. Hwang D, Scollard D, Byrne J, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998; 90 (6): 455-60
54. Deininger MH, Weller M, Streffer J et al. Patterns of cyclooxygenase-1 and -2 expression in human gliomas in vivo. Acta Neuropathol (Berl) 1999; 98 (3): 240-4
55. Joki T, Heese O, Nikas DC, et al. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res 2000; 60 (17): 4926-31
56. Karim MM, Hayashi Y, Inoue M, et al. Cox-2 expression in retinoblastoma. Am J Ophthalmol 2000; 129 (3): 398-401
57. Shono T, Tofilon PJ, Bruner JM, et al. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res 2001 Jun 1; 61 (11): 4375-81
58. Ferrandina G, Lauriola L, Distefano MG, et al. Increased Cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol 2002 Feb 15; 20 (4): 973-81
59. Gaffney DK, Holden J, Davis M, et al. Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2001; 49 (5): 1213-7
60. Kulkarni S, Rader JS, Zhang F, et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 2001; 7 (2): 429-34
61. Ryu HS, Chang KH, Yang HW, et al. High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion. Gynecol Oncol 2000; 76 (3): 320-5
62. Kandil HM, Tanner G, Smalley W, et al. Cyclooxygenase-2 expression in Barrett's esophagus. Dig Dis Sci 2001; 46 (4): 785-9
63. Morris CD, Armstrong GR, Bigley G, et al. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001; 96 (4): 990-6
64. Shirvani VN, Ouatu-Lascar R, Kaur BS, et al. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 2000; 118 (3): 487-96
65. Zimmermann KC, Sarbia M, Weber AA, et al. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999; 59 (1): 198-204
66. Wilson KT, Fu S, Ramanujam KS, et al. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998; 58 (14): 2929-34
67. Kawabe A, Shimada Y, Uchida S, et al. Expression of Cyclooxygenase-2 is associated with carcinogenesis of the lower part of thoracic esophageal squamous cell carcinoma and p53 expression. Oncology 2002; 62 (1): 46-54
68. Ratnasinghe D, Tangrea J, Roth MJ, et al. Expression of cyclooxygenase-2 in human squamous cell carcinoma of the esophagus; an immunohistochemical survey. Anticancer Res 1999; 19 (1A): 171-4
69. van Rees BP, Saukkonen K, Ristimaki A, et al. Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathol 2002 Feb; 196 (2): 171-9
70. Rajnakova A, Moochhala S, Goh PM, et al. Expression of nitric oxide synthase, cyclooxygenase, and p53 in different stages of human gastric cancer. Cancer Lett 2001 Oct 30; 172 (2): 177-85
71. Akhtar M, Cheng Y, Magno RM, et al. Promoter methylation regulates helicobac-ter pylori-stimulated cyclooxygenase-2 expression in gastric epithelial cells. Cancer Res 2001 Mar 1; 61 (6): 2399-403
72. Uefuji K, Ichikura T, Mochizuki H. Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas. J Surg Oncol 2001; 76 (1): 26-30
73. Ohno R, Yoshinaga K, Fujifa T, et al. Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma. Cancer 2001; 91 (10): 1876-81
74. Uefuji K, Ichikura T, Mochizuki H. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res 2000; 6 (1): 135-8
75. Lim HY, Joo HJ, Choi JH, et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res 2000; 6 (2): 519-25
76. Ratnasinghe D, Tangrea JA, Roth MJ, et al. Expression of cyclooxygenase-2 in human adenocarcinomas of the gastric cardia and corpus. Oncol Rep 1999; 6 (5): 965-8
77. Yamamoto H, Itoh F, Fukushima H, et al. Overexpression of cyclooxygenase-2 protein is less frequent in gastric cancer with microsatellite instability. Int J Cancer 1999; 84 (4): 400-3
78. Murata H, Kawano S, Tsuji S, et al. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 1999; 94 (2): 451-5
79. Uefuji K, Ichikura T, Mochizuki H, et al. Expression of cyclooxygenase-2 protein in gastric adenocarcinoma. J Surg Oncol 1998; 69 (3): 168-72
80. Soydan AS, Gaffen JD, Weech PK, et al. Cytosolic phospholipase A2, cyclo-oxygenases and arachidonate in human stomach tumours. Eur J Cancer 1997; 33 (9): 1508-12
81. Ristimaki A, Honkanen N, Jankala H, et al. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997; 57 (7): 1276-80
82. Bae SH, Jung ES, Park YM, et al. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 Inhibitor, NS-398. Clin Cancer Res 2001; 7 (5): 1410-8
83. Koga H, Sakisaka S, Ohishi M, et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor differentiation. Hepatology 1999; 29 (3): 688-96
84. Kondo M, Yamamoto H, Nagano H, et al. Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin Cancer Res 1999; 5 (12): 4005-12
85. Rahman MA, Dhar DK, Yamaguchi E, et al. Coexpression of inducible nitric oxide synthase and cox-2 in hepatocellular carcinoma and surrounding liver: possible involvement of cox-2 in the angiogenesis of hepatitis c virus-positive cases. Clin Cancer Res 2001; 7 (5): 1325-32
86. Shiota G, Okubo M, Noumi T, et al. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology 1999; 46 (25): 407-12
87. Wolff H, Saukkonen K, Anttila S, et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998; 58 (22): 4997-5001
88. Yoshimatsu K, Altorki NK, Golijanin D, et al. Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin Cancer Res 2001 Sep; 7 (9): 2669-74
89. Dohadwala M, Luo J, Zhu L, et al. Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem 2001; 276: 20809-12
90. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001; 7 (4): 861-7
91. Hosomi Y, Yokose T, Hirose Y, et al. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer 2000; 30 (2): 73-81
92. Ochiai M, Oguri T, Isobe T, et al. Cyclooxygenase-2 (COX-2) mRNA expression levels in normal lung tissues and non-small cell lung cancers. Jpn J Cancer Res 1999; 90 (12): 1338-43
93. Watkins DN, Lenzo JC, Segal A, et al. Expression and localization of cyclo-oxygenase isoforms in non-small cell lung cancer. Eur Respir J 1999; 14 (2): 412-8
94. Achiwa H, Yatabe Y, Hida T, et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999; 5 (5): 1001-5
95. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998; 58 (17): 3761-4
96. Huang M, Stolina M, Sharma S, et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998; 58 (6): 1208-16
97. Merati K, Said SM, Andea A, et al. Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters. Am J Clin Oncol 2001 Oct; 24 (5): 447-52
98. Kokawa A, Kondo H, Gotoda T, et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 2001; 91 (2): 333-8
99. Yip-Schneider MT, Barnard DS, Billings SD, et al. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 2000; 21 (2): 139-46
100. Molina MA, Sitja-Arnau M, Lemoine MG, et al. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999; 59 (17): 4356-62
101. Okami J, Yamamoto H, Fujiwara Y, et al. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res 1999; 5 (8): 2018-24
102. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999; 59 (5): 987-90
103. Uotila P, Valve E, Martikainen P, et al. Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res 2001; 29 (1): 23-8
104. Tanji N, Kikugawa T, Yokoyama M. Immunohistochemical study of cyclooxygenases in prostatic adenocarcinoma; relationship to apoptosis and Bcl-2 protein expression. Anticancer Res 2000; 20 (4): 2313-9
105. Madaan S, Abel PD, Chaudhary KS, et al. Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU Int 2000; 86 (6): 736-41
106. Kirschenbaum A, Klausner AP, Lee R, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology 2000; 56 (4): 671-6
107. Gupta S, Srivastava M, Ahmad N, et al. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000; 42 (1): 73-8
108. Yoshimura R, Sano H, Masuda C, et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000; 89 (3): 589-96
109. Tjandrawinata RR, Dahiya R, Hughes-Fulford M. Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer 1997; 75 (8): 1111-8
110. Peng JP, Su CY, Chang HC, et al. Overexpression of cyclo-oxygenase 2 in squamous cell carcinoma of the hypopharynx. Hum Pathol 2002 Jan; 33 (1): 100-4
111. Chan G, Boyle JO, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999; 59 (5): 991-4
112. Gallo O, Franchi A, Magnelli L, et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer: implications for tumor angiogenesis and metastasis. Neoplasia 2001; 3 (1): 53-61.
113. Nathan CA, Leskov IL, Lin M, et al. COX-2 expression in dysplasia of the head and neck: correlation with elF4E. Cancer 2001 Oct 1; 92 (7): 1888-95
114. Higashi Y, Kanekura T, Kanzaki T. Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: evidence for growth suppression by inhibiting COX-2 expression. Int J Cancer 2000; 86 (5): 667-71
115. Muller-Decker K, Reinerth G, Krieg P, et al. Prostaglandin-H-synthase isozyme expression in normal and neoplastic human skin. Int J Cancer 1999; 82 (5): 648-56
116. Buckman SY, Gresham A, Hale P, et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998; 19 (5): 723-9
117. Denkert C, Kobel M, Berger S, et al. Expression of cyclooxygenase-2 in human malignant melanoma. Cancer Res 2001 Jan 1; 61 (1): 303-8
118. Salmenkivi K, Haglund C, Ristimaki A, et al. Increased expression of cyclooxygenase-2 in malignant pheochromocytomas. J Clin Endocrinol Metab 2001 Nov; 86 (11): 5615-9
119. Specht MC, Tucker ON, Hocever M, et al. Cyclooxygenase-2 expression in thyroid nodules. J Clin Endocrinol Metab 2002 Jan; 87 (1): 358-63
120. Gaffney DK, Holden J, Zempolich K, et al. Elevated COX-2 expression in cervical carcinoma: reduced cause-specific survival and pelvic control. Am J Clin Oncol 2001 Oct; 24 (5): 443-6
121. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87 (5): 803-9
122. Williams CS, Tsujii M, Reese J, et al. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000; 105 (11): 1589-94
123. Chulada PC, Thompson MB, Mahler JF, et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000; 60 (17): 4705-8
124. Neufang G, Furstenberger G, Heidt M, et al. Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin. Proc Natl Acad Sci U S A 2001 Jun 19; 98 (13): 7629-34
125. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93 (5): 705-16
126. Grossman EM, Longo WE, Panesar N, et al. The role of cyclooxygenase enzymes in the growth of human gall bladder cancer cells. Carcinogenesis 2000; 21 (7): 1403-9
127. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83 (3): 493-501
128. Nolan RD, Danilowicz RM, Eling TE. Role of arachidonic acid metabolism in the mitogenic response of BALB/c 3T3 fibroblasts to epidermal growth factor. Mol Pharmacol 1988 Jun; 33 (6): 650-6
129. Imagawa W, Bandyopadhyay GK, Wallace D, et al. Growth stimulation by PGE2 and EGF activates cyclic AMP-dependent and -independent pathways in primary cultures of mouse mammary epithelial cells. J Cell Physiol 1988 Jun; 135 (3): 509-15.
130. McKenzie KE, Bandyopadhyay GK, Imagawa W, et al. Omega-3 and omega-6 fatty acids and PGE2 stimulate the growth of normal but not tumor mouse mammary epithelial cells: evidence for alterations in the signaling pathways in tumor cells. Prostaglandins Leukot Essent Fatty Acids 1994 Dec; 51 (6): 437-43
131. Marnett LJ. Aspirin and related nonsteroidal anti-inflammatory drugs as chemopreventive agents against colon cancer. Prev Med 1995; 24 (2): 103-6
132. Wiese FW, Thompson PA, Kadlubar FF. Carcinogen substrate specificity of human COX-1 and COX-2. Carcinogenesis 2001 Jan; 22 (1): 5-10
133. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82 (1): 4-6
134. Koki AT, Leahy KM, Masferrer JL. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin Investig Drugs 1999; 8 (10): 1623-38
135. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 1997; 94 (7): 3336-40
136. Cianchi F, Cortesini C, Bechi P, et al. Up-regulation of cyclooxygenase-2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 2001 Dec; 121 (6): 1339-47
137. Anderson WF, Umar A, Viner JL, et al. The role of cyclooxygenase inhibitors in cancer prevention. Curr Pharm Des 2002; 8: 99-110
138. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988; 48 (15): 4399-404
139. Thun MJ, Namboodiri MM, Heath Jr CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325 (23): 1593-6
140. Thun MJ, Namboodiri MM, Calle EE, et al. Aspirin use and risk of fatal cancer. Cancer Res 1993; 53 (6): 1322-7
141. Giovannucci E, Rimm EB, Stampfer MJ, et al. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994; 121 (4): 241-6
142. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995; 333 (10): 609-14
143. Garcia-Rodriguez LA, Heuerta-Alvarez C. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspinn nonsteroidal antiinflammatory drugs. Epidemiology 2001; 12: 88-93
144. Garcia-Rodriguez LA, Huerta-Alvarez C. Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: a pooled analysis of published studies and a new population-based study. Epidemiology 2000; 11 (4): 376-81
145. Giovannucci E. The prevention of colorectal cancer by aspirin use. Biomed Pharmacother 1999; 53 (7): 303-8
146. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflanimatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002 Feb 20; 94 (4): 252-66
147. Paganin-Hill A. Aspirin and colorectal cancer: the Leisure World cohort revisited. Prev Med 1995; 24 (2): 113-5
148. Sturmer T, Glynn RJ, Lee IM, et al. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians Health Study. Ann Intern Med 1998; 128 (9): 713-20
149. Peleg II, Lubin MF, Cotsonis GA, et al. Long-term use of nonsteroidal anti-inflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia. Dig Dis Sci 1996; 41 (7): 1319-26
150. Sandler RS, Galanko JC, Murray SC, et al. Aspirin and Gansteroidal anti-inflammatory agents and risk for colorectal adenomas. Gastroenterology 1998; 114 (3): 441-7
151. Brener-Katschinski B, Nemes K, Rump B, et al. Long-term use of nonsteroidal antiinflammatory drugs and the risk of colorectal adenomas: the Colorectal Adenoma Study Group. Digestion 2000; 61 (2): 129-34
152. Martinez ME, McPherson RS, Levin B, et al. Aspirin and other nonsteroidal anti-inflammatory drugs and risk of colorectal adenomatous polyps among endoscoped individuals. Cancer Epidemiol Biomarkers Prev 1995; 4 (7): 703-7
153. Suh O, Mettlin C, Petrelli NJ. Aspirin use, cancer, and polyps of the large bowel. Cancer 1993; 72 (4): 1171-7
154. Logan RF, Little J, Hawtin PG, et al. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. BMJ 1993; 307 (6899): 285-9
155. Tangrea JA, Albert PS, Lanza E, et al. Non-steroidal anti-inflammatory drug use is associated with reduced risk of colorectal adenomas: a prospective study [abstract]. Proc AACR 2001 Mar; 42: 177
156. Greenberg ER, Baron JA, Freeman DH, et al. Reduced risk of large-bowel adenomas among aspirin users: the Polyp Prevention Study Group. J Natl Cancer Inst 1993; 85 (11): 912-6
157. Pinczowski D, Ekbom A, Baron J, et al. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 1994; 107 (1): 117-20
158. Muscat JE, Stellman SD, Wynder EL. Nonsteroidal antiinflammatory drugs and colorectal cancer. Cancer 1994; 74 (7): 1847-54
159. Peleg II, Maibach HT, Brown SH, et al. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 1994; 154 (4): 394-9
160. Freedman AN, Michalek AM, Weiss HA, et al. Aspirin use and p53 expression in colorectal cancer. Cancer Detect Prev 1998; 22 (3): 213-8
161. Neugut AI, Rosenberg DJ, Ahsan H, et al. Association between coronary heart disease and cancers of the breast, prostate, and colon. Cancer Epidemiol Biomarkers Prev 1998; 7 (10): 869-73
162. Bucher C, Jordan P, Nickeleit V, et al. Relative risk of malignant tumors in analgesic abusers: effects of long-term intake of aspirin. Clin Nephrol 1999; 51 (2): 67-72
163. La Vecchia C, Negri E, Franceschi S, et al. Aspirin and colorectal cancer. Br J Cancer 1997; 76 (5): 675-7
164. Friedman GD, Coates AO, Potter JD, et al. Drugs and colon cancer. Pharmacoepidemiol Drug Safety 1998; 7: 99-106
165. Rosenberg L, Palme JR, Zauber AG, et al. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 1991; 83 (5): 355-8
166. Coogan PF, Rosenberg L, Louik C, et al. NSAIDs and risk of colorectal cancer according to presence or absence of family history of the disease. Cancer Causes Control 2000; 11 (3): 249-55
167. Langman MJ, Cheng KK, Gilman EA, et al. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000; 320 (7250): 1642-6
168. Muller AD, Sonnenberg A, Wasserman IH. Diseases preceding colon cancer: a case-control study among veterans. Dig Dis Sci 1994; 39 (11): 2480-4
169. Bansal P, Sonnenberg A. Risk factors of colorectal cancer in inflammatory bowel disease. Am J Gastroenterol 1996; 91 (1): 44-8
170. Reeves MJ, Newcomb PA, Trentham-Dietz A, et al. Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 1996; 5 (12): 955-60
171. Rosenberg L, Louik C, Shapiro S. Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma. Cancer 1998; 82 (12): 2326-33
172. Collet JP, Sharpe C, Belzile E, et al. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer 1999; 81 (1): 62-8
173. Cibere J, Sibley J, Haga M. Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 1997; 40 (9): 1580-6
174. Kauppi M, Pukkala E, Isomaki H. Low incidence of colorectal cancer in patients with rheumatoid arthritis. Clin Exp Rheumatol 1996; 14 (5): 551-3
175. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study [abstract]. Epidemiology 1994; 5 (2): 138-46
176. Paganini-Hill A. Aspirin and colorectal cancer [editorial]. BMJ 1993; 307 (6899): 278-9
177. Paganini-Hill A. Aspirin and the prevention of colorectal cancer: a review of the evidence. Semin Surg Oncol 1994; 10 (3): 158-64
178. Paganini-Hill A, Chao A, Ross RK, et al. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 1989; 299 (6710): 1247-50
179. Paganini-Hill A, Hsu G, Ross RK, et al. Aspirin use and incidence of large-bowel cancer in a California retirement community [letter]. J Natl Cancer Inst 1991; 83 (16): 1182-3
180. Paganini-Hill A, Hsu G, Ross RK, et al. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1992; 326 (19): 1290; discussion 1290-1
181. Smalley W, Ray WA, Daugherty J, et al. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med 1999; 159 (2): 161-6
182. Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993; 85 (4): 307-11
183. Castelao JE, Yuan JM, Gago-Dominguez M, et al. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 2000; 82 (7): 1364-9
184. Coogan PF, Rao SR, Rosenberg L, et al. The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer. Prev Med 1999; 29 (2): 72-6
185. Egan KM, Stampfer MJ, Giovannucci E, et al. Prospective study of regular aspirinuse and the risk of breast cancer. J Natl Cancer Inst 1996; 88 (14): 988-93
186. Harris RE, Kasbari S, Farrar WB. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep 1999; 6 (1): 71-3
187. Harris RE, Namboodiri KK, Farrar WB. Nonsteroidal antiinflammatory drugs
188. Sharpe CR, Collet JP, McNutt M, et al. Nested study of the effects-of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer 2000; 83 (1): 112-20.
189. Funkhouser EM, Sharp GB. Aspirin and reduced risk of esophageal carcinoma. Cancer 1995; 76 (7): 1116-9
190. Farrow DC, Vaughan TL, Hansten PD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998; 7 (2): 97-102
191. Zaridze D, Borisova E, Maximovitch D, et al. Aspirin protects against gastric cancer: results of a case-control study from Moscow, Russia. Int J Cancer 1999; 82 (4): 473-6
192. Nelson JE, Harris RE. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 2000; 7: 169-70
193. Norrish AE, Jackson RT, McRae CU. Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 1998 Aug 12; 77 (4): 511-5
194. Kearney D, Crump C, Maynard C. Aspirin and NSAID-requiring conditions and the risk of esophageal carcinoma [abstract]. Gastroenterology 2002; 122: A71
195. Harris RE, Beebe-Donk J, Namboodiri KK. Inverse association of non-steroidal anti-inflammatory drugs and malignant melanoma among women. Oncol Rep 2001; 8 (3): 655-7
196. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst 1998; 90 (21): 1609-20
197. Smalley WE, DuBois RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 1997; 39: 1-20
198. Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 1996; 56 (20): 4566-9
199. Kawamori T, Rao CV, Seibert K, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998; 58 (3): 409-12
200. Reddy BS, Hirose Y, Lubet R, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000; 60 (2): 293-7
201. Jacoby RF, Seibert K, Cole CE, et al. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive ind therapeutic agent in the Min mousc model of adenomatous polyposis. Cancer Res 2000; 60 (18): 5040-4
202. Sasai H, Masaki M, Wakitani K. Suppression of polypogenesis in a new mouse strain with a truncated Apc(Delta474) by a novel COX-2 inhibitor, JTE-522. Carcinogenesis 2000; 21 (5): 953-8
203. Yoshimi N, Kawabata K, Hara A, et al. Inhibitory effect of NS-398, a selective cyclooxygenase-2 inhibitor, on azoxymethane-induced aberrant crypt foci in colon carcinogenesis of F344 rats. Jpn J Cancer Res 1997; 88 (11): 1044-51
204. Fukutake M, Nakatsugi S, Isoi T, et al. Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice. Carcinogenesis 1998; 19 (11): 1939-42
205. Nakatsugi S, Fukutake M, Takahashi M, et al. Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase-2 inhibitor, in Min mice. Jpn J Cancer Res 1997; 88 (12): 1117-20
206. Yoshimi N, Shimizu M, Matsunaga K, et al. Chemopreventive effect of N-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide (NS-398), a selective cyclooxygenase-2 inhibitor, in rat colon carcinogenesis induced by azoxymethane. Jpn J Cancer Res 1999; 90 (4): 406-12
207. Oshima M, Murai N, Kargman S, et al. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001; 61 (4): 1733-40
208. Lal G, Ash C, Hay K, et al. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor. Cancer Res 2001 Aug 15; 61 (16): 6131-6
209. Harris RE, Alshafie GA, Abgu-Issa H, et al. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000; 60 (8): 2101-3
210. Matsunaga K, Yoshimi N, Yamada Y, et al. Inhibitory effects of nabumetone, a cyclooxygenase-2 inhibitor, and esculetin, a lipoxygenase inhibitor, on N-methyl-N-nitrosourea-induced mammary carcinogenesis in rats. Jpn J Cancer Res 1998 May; 89 (5): 496-501
211. Fischer SM, Lo HH, Gordon GB, et al. Chemopreventivc activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 1999; 25 (4): 231-40
212. Pentland AP, Schoggins JW, Scott GA, et al. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 1999; 20 (10): 1939-44
213. Muller-Decker K, Kopp-Schneider A, Marks F, et al. Localization of prostaglandin H synthase isoenzymes in murine epidermal tumors: suppression of skin tumor promotion by inhibition of prostaglandin H synthase-2. Mol Carcinog 1998; 23 (1): 36-44
214. Grubbs CJ, Lubet RA, Koki AT, et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 2000; 60 (20): 5599-602
215. Okajima E, Denda A, Ozono S, et al. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res 1998; 58 (14): 3028-31
216. Li Z, Shimada Y, Kawabe A, et al. Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by JTE-522, a selective COX-2 inhibitor. Carcinogenesis 2001 Apr; 22 (4): 547-51
217. Rioux N, Castonguay A. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res 1998; 58 (23): 5354-60
218. Shiotani H, Denda A, Yamamoto K, et al. Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-l-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. Cancer Res 2001 Feb 15; 61 (4): 1451-6
219. Torrance CJ, Jackson PE, Montgomery E, et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 2000; 6 (9): 1024-8
220. Sansom OJ, Stark LA, Dunlop MG, et al. Suppression of intestinal and mammary neoplasia by lifetime administration of aspirin in Apc(Min/+) and Apc(Min/+), Msh2(-/-) mice. Cancer Res 2001 Oct 1; 61 (19): 7060-4
221. Mahmoud NN, Boolbol SK, Dannenberg AJ, et al. The sulfide metaboloite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis 1998; 19 (1): 87-91
222. Mahmoud NN, Dannenberg AJ, Mestre J, et al. Aspirin prevents tumors in a murine model of familial adenomatous polyposis. Surgery 1998; 124 (2): 225-31
223. Boolbol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996; 56 (11): 2556-60
224. Hansen-Petrik MB, McEntee MF, Jull B, et al. Prostaglandin E2 protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in ApcMin/+ mice. Cancer Res 2002 Jan 1; 62 (2): 403-8
225. Wechter WJ, Murray Jr ED, Kantoci D, et al. Treatment and survival study in the C57BL/6J-APC(Min)/+(Min) mouse with R-flurbiprofen. Life Sci 2000 Jan 14; 66 (8): 745-53
226. Robertson FM, Parrett ML, Joarder FS, et al. Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinomas. Cancer Lett 1998 Jan 9; 122 (1-2): 165-75
227. Yao R, Rioux N, Castonguay A, et al. Inhibition of COX-2 and induction of apoptosis: two determinants of nonsteroidal anti-inflammatory drugs' chemopreventive efficacies in mouse lung tumorigenesis. Exp Lung Res 2000; 26 (8): 731-42
228. Castonguay A, Rioux N, Duperron C, et al. Inhibition of lung tumorigenesis by NSAIDS: a working hypothesis. Exp Lung Res 1998; 24 (4): 605-15
229. Hawk E, Lubet R, Limburg P. Chemoprevention in hereditary colorectal cancer syndromes. Cancer 1999; 86 (11 Suppl.): 2551-63
230. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983; 24 (1): 83-7
231. Chameau J, D'Aubigny N, Burtin P, et al. Rectal micropolyps after total colectomy in familial polyposis: efficacy of sulindac. Gastroenterol Clin Biol 1990; 14 (2): 153-7
232. Friend WG. Sulindac suppression of colorectal polyps in Gardner's syndrome. Am Fam Physician 1990 Mar; 41 (3): 891-4
233. Gonzaga RA, Lima FR, Carneiro S, et al. Sulindac treatment for familial polyposis coli [letter]. Lancet 1985 Mar 30: I (8431): 751
234. Giardiello FM, Spannhake EW, DuBois RN, et al. Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis. Dig Dis Sci 1998; 43 (2): 311-6
235. Iwama T, Imajo M. Mishima Y. Is sulindac effective for familial adenomatous polyposis? Int J Colorectal Dis 1991; 6: 235
236. Muller A, Hurlimann R, Meyenberger C, et al. Sulindac in familial adenomatous polyposis coli-preliminary findings of a prospective study. Schweiz Med Wochenschr 1994; 124 (15): 651-4
237. Niv Y, Fraser GM. Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy. Gastroenterology 1994; 107 (3): 854-7
238. Rigau J, Pique JM, Rubio E, et al. Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med 1991 Dec 15; 115 (12): 952-4
239. Spagnesi MT, Tonelli F, Dolara P, et al. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology 1994; 106 (2): 362-6
240. Tonelli F, Valanzano R, Dolara P. Sulindac therapy of colorectal polyps in familial adenomatous polyposis. Dig Dis 1994; 12 (5): 259-64
241. Tonelli F, Valanzano R. Sulindac in familial adenomatous polyposis [letter]. Lancet 1993; 342 (8879): 1120
242. Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991; 101 (3): 635-9
243. Nugent KP, Farmer KC, Spigelman AD, et al. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993; 80 (12): 1618-9
244. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328 (18): 1313-6
245. Matsuhashi N, Nakajima A, Shinohara K, et al. Rectal cancer after sulindac therapy for a sporadic adenomatous colonic polyp. Am J Gastroenterol 1998 Nov; 93 (11): 2261-6
246. Lynch HT, Thorson AG, Smyrk T. Rectal cancer after prolonged sulindac chemoprevention: a case report. Cancer 1995; 75 (4): 936-8
247. Thorson AG, Lynch HT, Smyrk TC. Rectal cancer in FAP patient after sulindac [letter]. Lancet 1994; 343 (8890): 180
248. Seow-Choen F, Vijayan V, Keng V. Prospective randomized study of sulindac versus calcium and calciferol for upper gastrointestinal polyps in familial adenomatous polyposis. Br J Surg 1996 Dec; 83 (12): 1763-6
249. Richard CS, Berk T, Bapat BV, et al. Sulindac for periampullary polyps in FAP patients. Int J Colorectal Dis 1997; 12 (1): 14-8
250. Parker AL, Kadakia SC, Maccini DM, et al. Disappearance of duodenal polyps in Gardner's syndrome with sulindac therapy. Am J Gastroenterol 1993 Jan; 88 (1): 93-4
251. Debinski HS, Trojan J, Nugent KP, et al. Effect of sulindac on small polyps in familial adenomatous polyposis. Lancet 1995 Apr 1; 345 (8953): 855-6
252. Waddell WR, Ganser GF, Cerise EJ, et al. Sulindac for polyposis of the colon. Am J Surg. 1989; 157 (1): 175-9
253. Windc G, Gumbinger HG, Osswald H, et al. The NSAID sulindac reverses rectal adcnomas in colectomized patients with familial adenomatous polyposis: clinical results of a dose-finding study on rectal sulindac administration. Int J Colorectal Dis 1993; 8 (1): 13-7
254. Winde G, Schmid KW, Brandt B, et al. Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis. Dis Colon Rectum 1997; 40 (10): 1156-68; discussion 1168-9
255. Winde G, Schmid KW, Schlegel W, et al. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment; advantages of a low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months. Dis Colon Rectum 1995; 38 (8): 813-30
256. van Stolk R, Stoner G, Hayton WL, et al. Phase I trial of exisulind (sulindac sulfone, FGN-1) asa chemopreventive agent in patients with familial adenomatous polyposis. Clin Cancer Res 2000; 6 (1): 78-89
257. Hirata K, Itoh H, Ohsato K. Regression of rectal polyps by indomethacin suppository in familial adenomatous Polyposis: report of two cases. Dis Colon Rectum 1994; 37 (9): 943-6
258. Hirota C, Iida M, Aoyagi K, et al. Effect of indomethacin suppositories on rectal polyposis in patients with familial adenomatous polyposis. Cancer 1996; 78 (8): 1660-5
259. Dolara P, Caderni G, Tonelli F. Nimesulide, a selective anti-inflammatory cyclooxygenase-2 inhibitor, does not affect polyp number and mucosil proliferation in familial adenomatous polyposis [letter]. Scand J Gastroenterol 1999; 34 (11): 1168
260. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342 (26): 1946-52
261. Phillips RK, Wallace MH, Lynch P, et al. A randomised, double-blind, placebo-controlled study of celecoxib, a selective cyclooxygenase-2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut. 2002; 50: 857-60
262. Hixson LJ, Earnest DL, Fennerty MB, et al. NSAID effect on sporadic colon polyps. Am J Gastroenterol 1993; 88 (10): 1652-6
263. Matsuhashi N, Nakajima A, Fukushima Y, et al. Effects of sulindac on sporadic colorectal adenomatous polyps. Gut 1997; 40 (3): 344-9
264. Ladenheim J, Garcia G, Titzer D, et al. Effect of sulindac on sporadic colonic polyps. Gastroenterology 1995; 108 (4): 1083-7
265. Gann PH, Manson JE, Glynn RJ, et al. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993; 85 (15): 1220-4
266. Carbone PP, Douglas JA, Larson PO, et al. Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine. Cancer Epidemiol Biomarkers Prev 1998 Oct; 7 (10): 907-12
267. Calaluce R, Earnest DL, Heddens D, et al. Effects of piroxicam on prostaglandin E2 levels in rectal mucosa of adenomatous polyp patients: a randomized phase IIb trial. Cancer Epidemiol Biomarkers Prev 2000 Dec; 9 (12): 1287-92
268. Chow HH, Earnest DL, Clark D, et al. Effect of subacute ibuprofen dosing on rectal mucosal prostaglandin E2 levels in healthy subjects with a history of resected polyps. Cancer Epidemiol Biomarkers Prev 2000 Apr; 9 (4): 351-6
269. Barnes CJ, Hamby-Mason RL, Hardman WE, et al. Effect of aspirin on prostaglandin E2 formation and transforming growth factor alpha expression in human rectal mucosa from individuals with a history of adenomatous polyps of the colon. Cancer Epidemiol Biomarkers Prev 1999 Apr; 8 (4 Pt 1): 311-5
270. Ruffin IV MT, Krishnan K, Rock CL, et al. Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose. J Natl Cancer Inst 1997 Aug 6; 89 (15): 1152-60
271. Baron JA, Cole BF, Mott LA, et al. Aspirin chemoprevention of colorectal adenomas [abstract]. Proc AACR 2002 Mar; 43: 669
272. Benamouzig R, Deyra J, Martin A, et al. Efficacy of lysin acetylsalicylate to prevent colorectal adenomas: one year results of the APACC Randomized Trial [abstract]. Gastroenterology 2002; 122: A70
273. Ding XZ, Tong WG, Adrian TE. Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res 2000; 20 (4): 2625-31
274. Hara A, Yoshimi N, Niwa M, et al. Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines. Jpn J Cancer Res 1997 Jun; 88 (6): 600-4.
275. Sawaoka H, Kawano S, Tsuji S, et al. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 1998; 274 (6 Pt 1): G1061-7.
276. Hsu AL, Ching TT, Wang DS, et al. The cyclooxygenase-2 inhibitor celecoxib induces apaptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000; 275 (15): 11397-403
277. Liu XH, Yao S, Kirschenbaum A, et al. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 1998; 58 (19): 4245-9
278. Nishimura G, Yanoma S, Mizuno H, et al. A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells. Jpn J Cancer Res 1999; 90 (10): 1152-62
279. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60 (5): 1306-11
280. Dormond O, Foletti A, Paroz C, et al. NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat Med 2001 Sep; 7 (9): 1041-7
281. Sharma RA, Gescher A, Plastaras JP, et al. Cyclooxygenase-2, malondialdehyde and pyrimidopurinone adducts of deoxyguanosine in human colon cells. Carcinogenesis 2001 Sep; 22 (9): 1557-60
282. McDougall CJ, Ngoi SS, Goldman IS, et al. Reduced expression of HLA class I and II antigens in colon cancer. Cancer Res 1990 Dec 15; 50 (24): 8023-7
283. Wilgus TA, Ross MS, Parrett ML, et al. Topical application of a selective cyclooxygenase inhibitor suppresses UVB mediated cutaneous inflammation. Prostaglandins Other Lipid Mediat 2000 Oct; 62 (4): 367-84
284. Zhang X, Morham SG, Langenbach R, et al. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med 1999; 190 (4): 451-9
285. Zhang L, Yu J, Park BH, et al. Role of BAX in the apoptotic response to anticancer agents. Science 2000; 290 (5493): 989-92
286. Kopelovich L, Fay JR, Glazer RI, et al. Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents. Molec Cancer Ther 2002; 1: 357-63
287. He TC, Chan TA, Vogelstein B, et al. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999; 99 (3): 335-45
288. Park BH, Vogelstein B, Kinzler KW. Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci U S A 2001 Feb 27; 98 (5): 2598-603
289. Yamamoto Y, Yin MJ, Lin KM. et al. Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem 1999 Sep 17; 274 (38): 27307-14
290. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998 Nov 5; 396 (6706): 77-80
291. Goppelt-Struebe M. Molecular mechanisms involved in the regulation of prostaglandin biosynthesis by glucocorticoids. Biochem Pharmacol 1997 May 15; 53 (10): 1389-95
292. Petrik MB, McEntee MF, Chiu CH, et al. Antagonism of arachidonic acid is linked to the antitumorigenie effect of dietary eicosapentacnoic acid in Apc(Min/+) mice. J Nutr 2000 May; 130 (5): 1153-8
293. Rao CV, Simi B, Wynn TT, et al. Modulating effect of amount and types of dietary fat on colonic mucosal phospholipase A2, phosphatidylinositol-specific phospholipase C activities, and cyclooxygenase metabolite formation during different stages of colon tumor promotion in male F344 rats. Cancer Res 1996 Feb 1; 56 (3): 532-7
294. Rao CV, Hirose Y, Indranic C, et al. Modulation of experimental colon tumongenesis by types and amounts of dietary fatty acids. Cancer Res 2001 Mar 1; 61 (5): 1927-33
295. Hong KH, Bonventre JC, O'Leary E, et al. Deletion of cytosolic phospholipase A(2) suppresses Apc(Min)-induced tumorigenesis. Proc. Natl Acad Sci U S A 2001 Mar 27; 98 (7): 3935-9
296. Takaku K, Sonoshita M, Sasaki N, et al. Suppression of intestinal polyposis in Apc(delta 716) knockout mice by an additional mutation the cytosolic phospholipase A(2) gene. J Biol Chem 2000; 275 (44): 34013-6
297. Moser AR, Dove WF, Roth KA, et al. The Min (multiple intestinal neoplasia) mutation: its effect on gut epithelial cell differentiation and interaction with a modifier system. J Cell Biol 1992 Mar; 116 (6): 1517-26
298. Cormier RT, Hong KH, Halberg RB, et al. Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nat Genet 1997 Sep; 17 (1): 88-91
299. Sonoshita M, Takaku K, Sasaki N, et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med 2001; 7 (9): 1048-51
300. Seno H, Oshinta M, Ishikawa TO, et al. Cyclooxygenase 2- and Prostaglandin E(2) Receptor EP(2)-dependent Angiogenesis in Apc(Delta716) Mouse Intestinal Polyps. Cancer Res 2002 Jan 15; 62 (2): 506-11
301. Jabbour HN, Milne SA, Williams AR, ct al. Expression of COX-2 and PGE synthase and synthesis of PGE(2)in endometrial adenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. Br J Cancer 2001 Sep; 85 (7): 1023-31
302. Sheng H, Shao J, Washington MK, et al. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chcm 2001 May 25; 276 (21): 18075-81
303. Watanabe K, Kawamori T, Nakatsugi S, et al. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res 1999 Oct 15; 59 (20): 5093-6
304. Watanabe K, Kawamori T, Nakatsugi S, et al. Inhibitory I effect of a prostaglandin E rceeptor subtype EP(1) selective antagonist, ONO-8713, on development of azoxymethane-induced aberrant crypt foci in mice. Cancer Lett 2000; 156 (1): 57-61
305. Giardiello FM, Hamilton SR, Hylind LM, et al. Ornithine decarboxylase and polyamines in familial adenomatous polyposis. Cancer Res 1997 Jan 15; 57 (2): 199-201
306. Patchett SE, Alstead EM, Trzeciak L, et al. Rectal mucosal ornithine decarboxylase activity in familial adenomatous polyposis after ileorectal anastomosis. Gut 1994 Nov; 35 (11): 1624-6
307. Khan KN, Masferrer JL, Woerner BM, et al. Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon. Scand J Gastroenterol 2001 Aug; 36 (8): 865-9
308. Humar B, D'Orazio D, Albreht C, et al. Expression of putative anticancer targets in familial adenomatous polyposis and its association with the APC mutation status. Int J Oncol 2001 Dec; 19 (6): 1179-86
309. Katdare M, Kopelovich L, Telang N. Chemopreventive agents inhibit aberrant proliferation of the aneuploid phenotype in a colon epithelial cell line established from Apc 1638N [+/-] mouse. Ann N Y Acad Sci 2001 Dec; 952: 169-74
310. Nigro ND, Bull AW, Boyd ME. Inhibition of intestinal carcinogenesis in rats: effect of difluoromethylornithine with piroxicam or fish oil. J Natl Cancer Inst 1986 Dec; 77 (6): 1309-13
311. Jacoby RF, Cole CE, Tutsch K, et al. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res 2000 Apr 1; 60 (7): 1864-70
312. Li H, Schut HA, Conran P, et al. Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon. Carcinogcnesis 1999 Mar; 20 (3): 425-30
313. Rao CV, Tokumo K, Rigotty J, et al. Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, alpha- difluoromethylornithine, 16 alpha-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res 1991 Sep 1; 51 (17): 4528-34
314. Reddy BS, Nayini J, Tokumo K, et al. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha-difluoromethylomithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res 1990 May 1; 50 (9): 2562-8
315. Rivers JK, McLean DI. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses. Arch Dermatol 1997 Oct; 133 (10): 1239-42
316. Jenkins CA, Bruera E. Nonsteroidal anti-inflammatory drugs as adjuvant analgesics in cancer patients. Palliat Med 1999; 13 (3): 183-96
317. Yalcin S, Altundag K, Asil M, et al. Sublingual piroxicam for cancer pain. Med Oncol 1998; 15 (2): 137-9
318. Mercadante S. The use of anti-inflammatory drugs in cancer pain. Cancer Treat Rev 2001; 27 (1): 51-61
319. McDonnell FJ, Sloan JW, Hamann SR. Advances in cancer pain management. Curr Oncol Rep 2000 Jul; 2 (4): 351-7
320. Lundholm K, Gelin J, Hyltander A, et al. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 1994; 54 (21): 5602-6
321. Alshafie GA, Abou-Issa HM, Seibert K, et al. Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep 2000 Nov; 7 (6): 1377-81
322. Duffy CP, Elliott CJ, O'Connor RA, et al. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur J Cancer 1998 Jul; 34 (8): 1250-9
323. Goluboff ET, Shabsigh A, Saidi JA, et al. Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology 1999 Feb; 53 (2): 440-5
324. Jiang MC, Liao CF, Lee PH. Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells. Biochem Biophys Res Commun 2001 Apr 6; 282 (3): 671-7
325. Knapp DW, Glickman NW, Widmer WR, et al. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemother Pharmacol 2000; 46 (3): 221-6
326. Rozic JG, Chakraborty C, Lala PK. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer 2001 Aug 15; 93 (4): 497-506
327. Petersen C, Petersen S, Milas L, et al. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clin Cancer Res 2000 Jun; 6 (6): 2513-20
328. Tsubouchi Y, Mukai S, Kawahito Y, et al. Meloxicam inhibits the growth of non-small cell lung cancer. Anticancer Res 2000 Sep; 20 (5A): 2867-72
329. Pyo H, Choy H, Amorino GP, et al. A selective cyclooxygenase-2 inhibitor. NS-398, enhances the effect of radiation in vitro and in vivo referentially on the cells that express cyclooxygenase-2. Clin Cancer Res 2001 Oct; 7 (10): 2998-3005
330. Kobayashi S, Okada S, Hasumi T, et al. The marked anticancer effect of combined VCR, MTX, and indomethacin against drug-resistant recurrent small cell lung carcinoma after conventional chemotherapy: report of a case. Surg Today 1999; 29 (7): 666-9
331. Yoshinaga K, Teramura M, Iwabe K, et al. Anti-lymphoma effect of naproxen and indomethacin in a patient with relapsed diffuse large B-cell lymphoma. Am J Hematol 2001 Mar; 66 (3): 220-3
332. Anderson WF, Umar A, Viner JL, et al. Potential role of NSAIDs and COX-2 blockade in cancer therapy. In: Harris RE, editor. Cyclooxygenase 2 (COX-2) blockade in cancer prevention and therapy. Totowa (NJ): The Humana Press Inc, 2002. 313-340
333. Mann M, Sheng H, Shao J, et al. Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 2001 Jun; 120 (7): 1713-9
334. Yip-Schneider MT, Sweeney CJ, Jung SH, et al. Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther 2001 Sep; 298 (3): 976-85
335. Roller A, Bahr OR, Streffer J, et al. Selective potentiation of drug cytotoxicity by NSAID in human glioma cells: the role of COX-1 and MRP. Biochem Biophys Res Commun 1999 Jun 16; 259 (3): 600-5
336. Milas L, Kishi K, Hunter N, et al. Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst 1999 Sep 1; 91 (17): 1501-4
337. Palayoor ST, Bump EA, Calderwood SK, et al. Combined antitumor effect of radiation and ibuprofen in human prostate carcinoma cells. Clin Cancer Res 1998 Mar; 4 (3): 763-71
338. Dicker AP, Williams TL, Grant DS. Targeting angiogenic processes by combination rofecoxib and ionizing radiation. Am J Clin Oncol 2001 Oct; 24 (5):438-42
339. Williams CS, Watson AJ, Sheng H, et al. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 2000 Nov 1; 60 (21): 6045-51
340. Goldman AP, Williams CS, Sheng H, et al. Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis 1998 Dec; 19 (12): 2195-9
341. Sheng H, Shao J, Kirkland SC, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997 May 1; 99 (9): 2254-9
342. Chiu CH, McEntee MF, Whelan J. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis. Cancer Res 1997; 57 (19): 4267-73
343. Wechter WJ, Leipold DD, Murray Jr ED, et al. E-7869 (R- flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res 2000 Apr 15; 60 (8): 2203-8
344. Mcikova-Kalicka K, Bojkova B, Adamckova E, et al. Preventive effect of indomethacin and melatonin on 7, 12-dimethybenz/a/anthracene-induced mammary carcinogenesis in female Sprague-Dawley rats: a preliminary report. Folia Biol (Praha) 2001; 47 (2): 75-9
345. Creagan ET, Buckner JC, Hahn RG, et al. An evaluation of recombinant leukocyte A interferon with aspirin in patients with metastatic renal cell cancer. Cancer 1988; 61 (9): 1787-91
346. Creagan ET, Twito DI, Johansson SL, et al. A randomized prospective assessment of recombinant leukocyte A human interferon with or without aspirin in advanced renal adenocarcinoma. J Clin Oncol 1991; 9 (12): 2104-9
347. Mertens WC, Bramwell VH, Banerjee D, et al. Sustained oral indomethacin and ranitidine with intermittent continuous infusion interleukin-2 in advanced renal cell carcinoma. Cancer Biother 1993; 8 (3): 229-33
348. Mertens WC, Bramwell VH, Gwadry-Sridhar F, et al. Effect of indomethacin plus ranitidine in advanced melanoma patients on high-dose interleukin-2. Lancet 1992 Aug 15; 340 (8816): 397-8
349. Mertens WC, Bramwell VH, Banerjee D, et al;. Sustained indomethacin and ranitidine with intermittent continuous infusion interleukin-2 in advanced malignant melanoma: a phase II study. Clin Oncol (R Coll Radiol) 1993; 5 (2): 107-13
350. Mertens WC, Lohmann RC. Oral indomethacin and ranitidine in advanced melanoma: a phase II study. Clin Oncol (R Coll Radiol) 1996; 8 (2): 112-5
351. Miller RL, Steis RG, Clark JW, et al. Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma. Cancer Res 1989 Apr 1; 49 (7): 1871-6
352. Janik JE, Miller LL, Longo DL, et al. Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma. J Natl Cancer Inst 1996 Jan 3; 88 (1): 44-9
353. Pillsbury III HC, Webster WP, Roscnman J. Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers. Arch Otolaryngol Head Neck Surg 1986 May; 112 (5): 552-3
354. Cross DS, Platt JL, Juhn SK, et al. Administration of a prostaglandin synthetase inhibitor associated with an increased immune cell infiltrate in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1992 May; 118 (5): 526-8
355. Sosman JA, Kohler PC, Hank JA, et al. Repetitive weekly cycles of interleukin-2, II: clinical and immunologic effects of dose, schedule, and addition of indomethacin. J Natl Cancer Inst 1988; 80 (18): 1451-61
356. Braun DP, Bonomi PD, Taylor IV SG, et al. Modification of the effects of cytotoxic chemotherapy on the immune responses of cancer patients with a nonsteroidal, antiinflammatory drug, piroxicam: a pilot study of the Eastern Cooperative Oncology Group. J Biol Response Mod 1987; 6 (3): 331-45
357. Sinicrope FA, Pazdur R, Levin B. Phase I trial of sulindac plus 5-fluorouracil and levamisole: potential adjuvant therapy for colon carcinoma. Clin Cancer Res 1996 Jan; 2 (1): 37-41
358. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340 (24): 1888-99
359. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998; 105 (1 Suppl. 2): 31S-8S
360. Larkai EN, Smith JL, Lidsky MD, et al. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987 Nov; 82 (11): 1153-8
361. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999 Apr; 26 Suppl. 56: 18-24
362. Bjorkman DJ. Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: risk factors and frequency of complications. Am J Med 1999 Dec 13; 107 (6A): 3S-8S; discussion 8S-10S
363. Whelton A, Maurath CJ, Verburg KM, et al. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther 2000 May; 7 (3): 159-75
364. Schafer AI. Effects of nonsteroidal anti-inflammatory therapy on platelets. Am J Med 1999 May 31; 106 (5B): 25S-36S
365. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345 (6): 433-42
366. Prescott SM. Is cyclooxygenase-2 the alpha and the omega in cancer? J Clin Invest 2000; 105 (11): 1511-3
367. Mizuno H, Sakamoto C, Matsuda K, et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997 Feb; 112 (2): 387-97
368. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med 2000; 343 (21): 1520-8
369. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis, the CLASS study, a randomized controlled trial: Celecoxib Long-term Arthritis Safety Study. JAMA-2000; 284 (10): 1247-55
370. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999 Nov 24; 282 (20): 1929-33
371. Mukherjec D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001 Aug; 286 (8): 954-9
372. Sanmuganathan PS, Ghahramani P, Jackson PR, et al. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001 Mar; 85 (3): 265-71
373. Merck COX-2 cardiovascular safety studies will enroll 30,000 subjects 'The Pink Sheet'. Chevy Chase (MD): F-D-C Reports, Inc, 2001: 12
374. Perazella MA, Eras J. Are selective COX-2 inhibitors nephrotoxic? Am J Kidney Dis 2000 May; 35 (5): 937-40
375. Rocha JL, Fernandez-Alonso J. Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib. Lancet 2001 Jun 16; 357 (9272): 1946-7
376. Dinchuk JE, Car BD, Focht RJ, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995 Nov 23; 378 (6555): 406-9
377. Komhoff M, Wang JL, Cheng HF, et al. Cyclooxygenase-2-selective inhibitors impair glomerulogenesis and renal cortical development. Kidney Int 2000 Feb; 57 (2): 414-22
378. Mersfelder TL, Stewart LR. Warfarin and celecoxib interaction. Ann Pharmacother 2000 Mar; 34 (3): 325-7
379. Haase KK, Rojas-Fernandez CH., Lane L, et al. Potential-interaction between celecoxib and warfarin. Ann Pharmacother 2000 May; 34 (5): 666-7
380. Santini G, Patrignani P, Sciulli MG, et al. The human pharmacology of monocyte cyclooxygenase 2 inhibition by cortisol and synthetic glucocorticoids. Clin Pharmacol Ther 2001 Nov; 70 (5): 475-83
381. Rao CV, Indranie C, Simi B, et al. Chemoprevent properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooygenase-2 inhibitors. Cancer Res 2001; 62: 165-70
382. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995 Aug 15; 123 (4): 241-9